Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Marvells all-stock agreement to acquire Lumentum has triggered a sharp selloff, with many traders criticizing the deals cost, shareholder dilution and long wait for completion. Others argue the combination could strengthen Marvells position in optical connectivity for AI data centers over the long term.

Marvells agreed all-stock acquisition of Lumentum dominates discussion, with LITE holders concerned that the fixed exchange ratio ties their value to Marvells share price through a lengthy closing process. Traders debate the strategic fit in AI optics against dilution, the deals terms, and whether the transaction will win shareholder approval; some see long-term potential while many criticize the near-term reaction.

A sharp selloff has traders focused on Usonas competing NDA filing and Compass Pathways still-pending completion of its own NDA, with investors looking to the upcoming earnings update for a clearer filing timeline. Some see Usona as a competitive threat and fault Compass management for delays, while others say the news was known and the drop reflects broader biotech weakness or an overreaction.

AMD is under pressure as Intels disappointing results and outlook have unsettled semiconductor investors, while broader concerns about AI spending and elevated valuations add to the selloff ahead of AMDs earnings. Traders are divided over whether the decline is sympathy selling that AMD can overcome or a warning sign, with the companys results and guidance seen as key tests.

Apples fiscal Q4 earnings and outlook dominate discussion, with traders focused on holiday-quarter iPhone demand and whether rising memory costs will pressure margins. Views are split between bulls expecting strong results and bears arguing that the stocks strong run and high valuation leave it vulnerable to a selloff, with the report also seen as a key test for broader tech sentiment.

APLD is under pressure amid a broader AI and data-center stock selloff, with traders focused on CEO Wes Cummins comments that substantial planned capacity still needs financing, fueling concerns about borrowing costs and possible dilution. Longs point to hyperscaler leases and demand, while bears want concrete financing progress.

Intels sharp post-earnings selloff is being attributed mainly to weaker-than-expected guidance, with traders pointing to supply constraints and soft PC demand despite a strong reported quarter. The community is split between buying the steep decline as an oversold opportunity and expecting further losses amid concerns about execution and foundry progress.

Micron is selling off alongside semiconductor and AI-related stocks as traders question whether AI spending and memory demand can sustain their recent pace; Kioxias cautious outlook has reinforced concerns about memory pricing and a possible cyclical slowdown. The debate pits those worries against bullish views that AI-driven demand and tight memory supply remain strong.

The selloff is being discussed alongside reports and speculation that Usona has submitted an NDA for its psilocybin treatment, potentially putting it ahead of Helus Pharma in the race to market; traders also note that Helus has not disclosed its Phase 3 results. Reactions are split between concern about competitive timing and the lack of data, and bullish anticipation of Heluss upcoming HLP003 readout, with some attributing the move to broader biotech weakness.

UPST is drawing attention amid a steep selloff and repeated 52-week lows, with bearish traders focused on the companys debt and liquidity, sensitivity to higher yields, and the risk that loan funding becomes harder to secure. Bulls counter that lending growth, new partnerships, a potential bank charter, and high short interest could support a recovery, but the dominant tone is frustration and concern over continued selling.